See more : Polyrizon Ltd. (PLRZ) Income Statement Analysis – Financial Results
Complete financial analysis of Cotinga Pharmaceuticals Inc. (COTQF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cotinga Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Medicenna Therapeutics Corp. (MDNA) Income Statement Analysis – Financial Results
- Reklaim Ltd. (MYIDF) Income Statement Analysis – Financial Results
- Wuxi Taiji Industry Limited Corporation (600667.SS) Income Statement Analysis – Financial Results
- 1Life Healthcare, Inc. (ONEM) Income Statement Analysis – Financial Results
- Aecc Aero Science and Technology Co.,Ltd (600391.SS) Income Statement Analysis – Financial Results
Cotinga Pharmaceuticals Inc. (COTQF)
About Cotinga Pharmaceuticals Inc.
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
| Metric | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 30.37K |
| Cost of Revenue | 83.85K | 170.68K | 182.44K | 172.64K | 1.01M | 835.54K | 658.77K |
| Gross Profit | -83.85K | -170.68K | -182.44K | -172.64K | -1.01M | -835.54K | -628.40K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,069.14% |
| Research & Development | 502.51K | 2.16M | 1.99M | 1.20M | 1.12M | 971.83K | 853.17K |
| General & Administrative | 1.29M | 2.52M | 2.89M | 1.56M | 1.90M | 1.71M | 1.64M |
| Selling & Marketing | 75.83K | 243.69K | 303.73K | 423.24K | 236.11K | 134.03K | 310.02K |
| SG&A | 1.42M | 2.60M | 3.01M | 1.85M | 2.17M | 1.88M | 1.99M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.92M | 4.76M | 5.00M | 3.05M | 2.10M | 1.88M | 1.99M |
| Cost & Expenses | 2.00M | 4.93M | 5.18M | 3.22M | 3.11M | 2.72M | 2.64M |
| Interest Income | 3.49K | 959.59 | 25.92K | 10.38K | 41.16K | 12.16K | 6.63K |
| Interest Expense | 0.00 | 1.44K | 2.36K | 1.00K | 64.22K | 20.15K | 1.25K |
| Depreciation & Amortization | 83.85K | 170.68K | 182.44K | 172.64K | 385.16K | 422.31K | 455.48K |
| EBITDA | -1.92M | -6.06M | -5.96M | -3.85M | -3.16M | -2.44M | -2.10M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7,107.99% |
| Operating Income | -2.00M | -4.93M | -5.18M | -3.22M | -3.18M | -2.72M | -2.61M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -8,607.76% |
| Total Other Income/Expenses | 38.50K | 2.43M | 534.47K | -101.08K | 40.64K | -16.47K | -11.63K |
| Income Before Tax | -1.97M | -3.84M | -4.65M | -4.02M | -3.15M | -2.73M | -2.61M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -8,584.58% |
| Income Tax Expense | 38.85K | -34.24K | -105.49K | -90.53K | -0.38 | 0.29 | 0.78 |
| Net Income | -2.01M | -3.81M | -4.54M | -3.93M | -3.15M | -2.73M | -2.61M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -8,584.58% |
| EPS | -0.09 | -0.24 | -0.31 | -0.31 | -0.29 | -0.31 | -0.35 |
| EPS Diluted | -0.09 | -0.24 | -0.31 | -0.31 | -0.29 | -0.31 | -0.35 |
| Weighted Avg Shares Out | 21.96M | 15.97M | 14.84M | 12.71M | 10.87M | 8.92M | 7.53M |
| Weighted Avg Shares Out (Dil) | 21.96M | 15.97M | 14.84M | 12.71M | 10.87M | 8.92M | 7.53M |
Source: https://incomestatements.info
Category: Stock Reports